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Background: We investigated the clinical relevance of a common variant, rs4820599, in the γ-glutamyltransferase
(GGT)1 gene, associated with the serum GGT level, in Japanese type 2 diabetes mellitus (T2DM) subjects.
Methods: We conducted a retrospective longitudinal study (4.9 ± 2.5 years) including 352 T2DM patients (T2DM
subjects) and a cross-sectional study including 796 health screening program participants (general subjects). A real-time
TaqMan allelic discrimination assay was used to identify the genotypes. Risk factors for a high brachial-ankle pulse wave
velocity (baPWV) (≥1750 cm/sec) or diabetic retinopathy (DR) were determined using a generalized estimating equations
approach, receiver operating characteristic (ROC) analysis or Cox proportional hazards model, etc.
Results: The frequency of the GGT1 G allele was 20.8% in the T2DM subjects, and no associations were found between
the GGT1 genotype and risk of T2DM. The mean log GGT values in the T2DM and general subjects were significantly
higher among G allele carriers than non-carriers. The G allele and a low HDL-C level were identified to be risk factors for
a high baPWV in the T2DM subjects [odds ratio (OR) 1.80, P = 0.008; OR 1.71, P = 0.03; respectively), and a significant
interactive effect between these factors was found on the risk of a high baPWV and DR. The HDL-C level at baseline
was a significant predictor of a high baPWV only in G allele carriers according to the ROC analysis. This result regarding
baPWV in the T2DM subjects was replicated in the general population. Meanwhile, the GGT1 genotype was not associated
with the risk of DR, although it affected the principal factors involved in the risk of DR, and a low HDL-C level was also
found to be a risk factor for DR only in G allele carriers.
Conclusions: We herein describe for the first time the significant interactive effects of the GGT1 G allele and a low HDL-C
level on a high baPWV and DR. These findings may encourage future clinical trials comparing the efficacy of agents
increasing the HDL-C levels among the GGT1 genotypes. However, well-designed studies in larger cohorts are
needed to confirm our results.
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The level of serum γ-glutamyltransferase (GGT), a
widely used index for excessive alcohol consumption
and/or liver dysfunction, has been found to be associated
with an increased risk of diabetes, metabolic syndrome
and cardiovascular disease (CVD), including hyperten-
sion, coronary heart disease (CHD) and heart failure
(HF), as well as both cardiovascular and all-cause mor-
tality [1-5]. The pro-oxidant effect of GGT is proposed
to be the biological mechanism linking GGT to various
cardiovascular events, as a strong GGT activity and the
GGT-mediated oxidation of low-density lipoprotein
cholesterol (LDL-C) have been identified in the core
tissue of atheromas, likely influencing plaque evolution
and rupture [6-8]. Most serum GGT is bound to lipo-
proteins, such as anti-atherogenic apolipoprotein (Apo)
A-I, contained in high-density lipoprotein cholesterol
(HDL-C), and atherogenic Apo B [6,8-11]. Huseby [10]
reported that 70% of the total serum GGT activity is
detected in association with HDL-C.
Classic ‘diabetic dyslipidemia’ is characterized by the
so-called atherogenic lipid triad, consisting of increased
levels of small dense LDL particles and triglyceride-rich
lipoproteins and a decreased level of HDL-C, associated
with an increase in non-HDL cholesterol [12-16]. After
the introduction of statins, clinical emphasis first fo-
cused on LDL-C lowering as the prime lipid target [12].
However, treated patients remained at high risk of car-
diovascular events despite receiving the best standards
of care, including high-dose statins [12-14,16,17]. Under
such conditions, a raised triglyceride concentration is
strongly associated with a low HDL-C level. Hence, the
Residual Risk Reduction Initiative defines atherogenic
dyslipidemia as the imbalance between Apo B and Apo
A-I containing lipoproteins and identified this factor to
be a key contributor to residual cardiovascular risks [17].
Next, the effect of potential HDL-C raising dominated
research, with less focus on triglycerides [12,13,15-17].
In the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial, the use of fenofibrate in patients with
T2DM receiving simvastatin who were at high risk of
cardiovascular disease greatly reduced the triglyceride
levels, although it hardly increased the HDL-C levels and
did not reduce cardiovascular risks [14]. Nevertheless, the
results of this trial suggest that fenofibrate reduces the risk
of CHD in patients with high levels of triglycerides and low
levels of HDL-C [14]. In 2014, a large meta-analysis of ran-
domized controlled trials of agents that increase the HDL-
C level, i.e. niacin, fibrates and cholesteryl ester transfer
protein inhibitors, reported that none of these drugs reduce
cardiovascular events in patients treated with statins [18].
Additionally, a recent study using an analytical approach
that accounts for the potential pleiotropic effects of single-
nucleotide polymorphisms (SNPs) on the triglyceride, LDL-C and HDL-C levels and risk of CHD simultaneously in a
large sample demonstrated that plasma triglyceride-rich
lipoproteins causally influence the risk of CHD rather than
low HDL-C [19]. Consequently, the classic HDL hypoth-
esis, defined as the concept that interventions to raise the
HDL-C concentration will reduce cardiovascular risks, is
gradually being replaced by the triglyceride hypothesis and
HDL function hypothesis [12-14,20-22]. On the other hand,
in patients with diabetic microvascular complications
(MVCs), a large prospective study of newly diagnosed
T2DM subjects showed that a 0.03 mmol/L increase in
HDL-C is associated with a 1% decrease in the MVC risk
and that patients achieving the HDL-C goals (>1.0 mmol/L
for males and 1.25 mmol/L for females) have a 11% lower
risk of MVC versus non-achievers [23]. The ACCORD trial
also demonstrated a large reduction in the progression of
diabetic retinopathy (DR) in patients with T2DM [24]. Fur-
thermore, Du et al. [25] identified extravasated Apo A-I
and Apo B in human diabetic eyes and revealed that native
HDL completely blocks oxidative stress and the apoptosis
of retinal pigment epithelial cells induced by heavily oxi-
dized glycated LDL, thereby suggesting an important new
role for extravasated and modified plasma lipoproteins in
promoting DR.
The serum level of GGT is influenced by both environ-
mental and genetic factors, and its heritability has been
estimated to be 52% [26]. Furthermore, genome-wide
association studies (GWAS) have identified an association
between the GGT1 gene loci and the GGT level in differ-
ent ethnic groups [27-29]. However, the association of
these loci with diabetes and/or CVD has not yet been re-
ported. We herein present for the first time the significant
interactive effects of a GGT1 variant, rs4820599, and low
HDL-C on a high pulse wave velocity (PWV), a surrogate
marker of arterial stiffness, and DR in Japanese subjects
with type 2 diabetes mellitus (T2DM).
Methods
We conducted a retrospective longitudinal study includ-
ing 352 patients with T2DM (231 males and 121 females,
60.0 ± 11.0 years: T2DM subjects) who had been treated
at the Jinnouchi Clinic, Diabetes Care Center for more
than six months between February 2002 and January 2011
and a cross-sectional study including 796 subjects (517
males and 279 females, 62.1 ± 12.4 years: general subjects)
who had participated in a health screening program at the
Japanese Red Cross Kumamoto Hospital Health Center.
Subjects with a positive serological test for hepatitis
viruses or hepatobiliary diseases other than fatty liver dis-
ease were excluded, whereas those with a history of CHD,
37 cases (10.5%) among the T2DM subjects and 37 cases
(4.6%) among the general subjects, were included. The
study protocol was approved by the institutional ethics
committees, and written informed consent was obtained
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ance with the Declaration of Helsinki.
Height and weight were measured using standard pro-
tocols, and the body mass index (BMI) was calculated.
Blood pressure (BP) was measured after the subjects
rested in the sitting position. Hypertension was defined as
a systolic BP of ≥ 140 mmHg, diastolic BP of ≥ 90 mmHg
or history of hypertension. The brachial-ankle PWV
(baPWV) was measured using an automated waveform
analyzer (Omron-Colin, Tokyo, Japan). Pneumatic cuffs
were wrapped around both upper arms and ankles and
connected to a plethysmographic sensor to determine the
volume pulse waveform. The highest value of baPWV
measured on either side of each patient was used for the
analysis. The value of baPWV at each follow-up visit was
dichotomized by 1,750 cm/sec, which has been reported
as the cut-off value for predicting the onset of stroke or
cardiovascular disease [30].
Fatty liver was diagnosed based on the following four
criteria: a diffuse hyperechoic echo texture (bright liver),
increased echo texture in comparison to the kidneys, vas-
cular blurring and deep attenuation [31]. DR was diag-
nosed by a professional ophthalmologist using direct
ophthalmoscopy or fundus fluorescein angiography. DR
was staged as no retinopathy, nonproliferative DR (NPDR)
or proliferative DR (PDR) according to the criteria deter-
mined at the third national ophthalmology conference
held in 1985. The occurrence of DR was defined as having
no sign of DR signs in both eyes at baseline with the devel-
opment of NPDR or PDR in either eye during the follow-
up period.
Laboratory tests were performed using the standard
methods of the Japan Society of Clinical Chemistry.
Dyslipidemia was defined as a triglyceride level of ≥
1.7 mmol/L, HDL-C level of < 1.0 mmol/L, LDL-C level
of ≥ 3.6 mmol/L or history of dyslipidemia. Diabetes was
defined as a fasting plasma glucose level of ≥ 7.0 mmol/L
or casual or two-hour glucose level of ≥ 11.1 mmol/L
after a 75 g oral glucose load test and a hemoglobin A1c
(HbA1c) level of ≥ 6.5% or history of diabetes. Patients
with type 1 diabetes were excluded based on their
clinical manifestations. Information regarding smoking
habits and alcohol intake was obtained via face-to-face
interviews with health care providers.
Genomic DNA was isolated from EDTA-preserved
blood samples using an automated DNA isolation system
(NA-3000) (Kurabo, Osaka, Japan). A real-time TaqMan
allelic discrimination assay was used to identify the GGT1
(rs4820599, assay ID: C_2446754_10) and aldehyde de-
hydrogenase 2 (ALDH2) (rs671, assay ID: C_11703892_10)
polymorphisms, and genotyping was performed according
to the manufacturer’s protocol (Applied Biosystems,
Tokyo, Japan). To ensure the quality of the genotyping,
we included DNA samples as internal controls, withhidden samples of known genotypes and negative
controls (water).
The data are presented as the mean ± standard devi-
ation or proportion for categorical variables. Student’s t-
test or a one-way analysis of variance and Fisher's exact
test were used for comparisons of continuous and cat-
egorical variables, respectively. Factors influencing the
GGT level were determined using a univariate linear re-
gression analysis. Independent models were used for the
analysis of the risk of a high baPWV (≥1,750 cm/sec),
with calculation of the odds ratio (OR) and 95% confi-
dence interval (95%CI) as well as the analysis of the
baPWV values obtained during the observation period,
with calculation of the adjusted partial regression coeffi-
cient (Β). We developed multiple regression models by
incorporating potentially confounding factors that showed
a P value of < 0.10 in the univariate models. Receiver oper-
ating characteristic (ROC) curves were determined to
evaluate the predictive performance of these factors for
detecting a high baPWV, with calculation of the area
under the curve (AUC). We also determined the cut-off
values for these factors as the point with the shortest
distance from the left upper corner of the graph.
Multivariate-adjusted hazard ratios (HRs) and 95%CIs for
the cumulative incidence of the development of DR were
examined using a Cox proportional hazards model. In
addition, the interactive effects of the GGT1 genotypes
and potentially confounding factors on the baPWV or
incidence of DR were assessed. A P value of < 0.05 was
considered to be statistically significant. All statistical ana-
lyses were performed using the SPSS software package
(version 17.0, IBM Japan Inc., Tokyo, Japan).
Results
The frequency of the GGT1 G allele was 20.8% and 22.1%
in the T2DM patients and general subjects, respectively.
The observed genotype frequency distributions in both
populations were consistent with the Hardy-Weinberg
equilibrium. No associations were found between the
GGT1 genotype and the risk of T2DM.
The mean follow-up duration in the T2DM subjects
was 4.9 ± 2.5 years. The clinical characteristics of the
T2DM subjects at baseline stratified by the GGT1 geno-
type are shown in Table 1. The GGT1 genotypes were
not significantly associated with any of the parameters.
However, the mean log GGT value was significantly
higher in GGT1 G allele carriers than in non-carriers
(1.52 ± 0.30 IU/L vs. 1.45 ± 0.30 IU/L, P = 0.04). The
other parameters did not differ between G allele carriers
and non-carriers.
Among the general subjects, the mean log GGT values
were also significantly higher in G allele carriers than in
non-carriers (1.47 ± 0.29 IU/L vs. 1.43 ± 0.29 IU/L, P =
0.03). Factors associated with the serum GGT level
Table 1 Clinical characteristics of T2DM stratified by the GGT1 genotype at baseline
A/A (n = 219) A/G (n = 120) G/G (n = 13) P-value
Female (%) 33.3 35.0 46.2 0.61
Age (years) 59.1 ± 10.5 61.6 ± 11.7 60.0 ± 10.6 0.13
BMI (kg/m2) 24.3 ± 3.9 24.0 ± 3.4 24.1 ± 2.9 0.72
Diabetes duration (years) 10.7 ± 8.2 10.7 ± 8.8 10.8 ± 6.2 1.00
HbA1c (%) 8.4 ± 2.0 8.3 ± 2.0 8.1 ± 2.0 0.66
Systolic BP (mmHg) 139.5 ± 19.5 137.9 ± 21.3 143.4 ± 17.2 0.57
Diastolic BP (mmHg) 83.4 ± 11.4 81.8 ± 12.9 85.9 ± 9.7 0.31
Triglycerides (mmol/L) 1.7 ± 1.2 1.9 ± 2.3 1.8 ± 1.9 0.50
HDL-C (mmol/L) 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.3 1.00
LDL-C (mmol/L) 3.2 ± 0.8 3.2 ± 0.9 3.1 ± 0.6 0.90
AST (IU/L) 24.8 ± 9.7 27.1 ± 14.2 25.2 ± 8.4 0.22
ALT (IU/L) 26.6 ± 16.4 30.2 ± 27.2 27.7 ± 11.6 0.31
GGT (IU/L) 36.6 ± 33.1 42.2 ± 36.8 43.6 ± 24.1 0.31
Log GGT (IU/L) 1.47 ± 0.30 1.51 ± 0.30 1.57 ± 0.26 0.08
Hypertension (%) 60.3 59.2 76.9 0.50
Dyslipidemia (%) 68.8 70.8 38.5 0.07
Ever smoker (%) 45.4 41.2 33.3 0.70
Alcohol intake (%) 51.4 46.7 38.5 0.52
Therapy components
Hypoglycemic agents
Oral hypoglycemic agents (%) 64.1 65.5 53.8 0.72
Insulin (%) 23.0 19.3 30.8 0.52
Antihypertensive agents
ACE inhibitors or ARBs(%) 20.3 16.0 7.7 0.44
Others(%) 23.5 26.9 23.1 0.77
Agents for hyperlipidemia
Fibrates(%) 0.9 0.8 7.7 0.15
Statins(%) 8.3 6.7 0.0 0.70
Others (%) 0.9 1.7 0.0 0.67
Data are percentages or mean ± standard deviation.
T2DM, type 2 diabetes mellitus; GGT, γ-glutamyltransferase; BMI, body mass index; HbA1c, hemoglobin A1c; BP, blood pressure; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ACE, angiotensin converting enzyme; ARB,
angiotensin II receptor blocker.
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are shown in Table 2. Fatty liver, dyslipidemia, ever-
smoking, drinking, the ALDH2*2 allele and the BMI,
transaminase, HbA1c, BP and triglyceride values were
significantly associated with the GGT levels, irrespective
of the GGT1 genotype, while the fasting plasma glucose,
HDL-C and LDL-C levels were significantly associated
with the GGT levels only in G allele carriers. In the
T2DM subjects, ever-smoking, drinking, the ALDH2*2
allele and the transaminase, diastolic BP and triglyceride
levels were significantly associated with the GGT levels,
irrespective of the GGT1 genotype, while the HbA1c
level was significantly associated with the GGT level
only in non-carriers (Additional file 1: Table S1).The GGT1 G allele was significantly associated with the
risk of a high baPWV (≥1,750 cm/sec) in the T2DM sub-
jects (OR 1.80, P = 0.008), in addition to age, hypertension,
the diabetes duration, low HDL-C (<1.0 mmol/L) and
drinking in the univariate models (Table 3). According to
the multiple regression models, age and hypertension were
found to be independent risk factors for a high baPWV ir-
respective of the GGT1 genotype (Table 4)(Additional file
1: Table S2). A significant interactive effect of the GGT1
genotype and the HDL-C level on the risk of a high
baPWV was observed in the generalized estimating equa-
tions approach (P = 0.04). Notably, the risk of a high
baPWV was significantly greater in G allele carriers with a
low HDL-C level (OR 2.49, P = 0.04) than in non-carriers
Table 2 Factors associated with the serum GGT levels stratified by the GGT1 genotype in the general subjects in the
univariate regression model
GGT (IU/L)
GGT1 A/A genotype GGT1 A/G or G/G genotype
B SE P-value B SE P-value
Fatty liver 24.61 5.24 <0.001 20.67 5.16 <0.001
Dyslipidemia 11.08 4.34 0.01 15.16 4.73 0.001
Ever smoking 19.68 4.31 <0.001 16.66 4.72 <0.001
Drinking 18.13 4.30 <0.001 15.94 4.70 0.001
ALDH2*2 allele −12.60 4.43 0.005 −5.90 4.80 0.22
BMI 3.76 0.70 <0.001 2.13 0.76 0.006
AST 3.24 0.17 <0.001 2.09 0.36 <0.001
ALT 1.67 0.14 <0.001 1.62 0.20 <0.001
HbA1c 8.07 1.81 <0.001 6.50 2.66 0.02
Systolic BP 0.27 0.13 0.04 0.35 0.15 0.02
Diastolic BP 0.84 0.20 <0.001 0.65 0.23 0.005
Triglycerides 0.16 0.03 <0.001 0.28 0.03 <0.001
Fasting plasma glucose 0.22 0.12 0.06 0.53 0.15 0.001
HDL-C 0.05 0.13 0.68 −0.38 0.14 0.005
LDL-C 0.001 0.09 0.99 0.18 0.09 0.04
Bold typeface indicates data that are significant only in the G allele carriers.
GGT, γ-glutamyltransferase; B, partial regression coefficient; SE; standard error; ALDH2, aldehyde dehydrogenase 2; BMI, body mass index; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; HbA1c, hemoglobin A1c; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol.
Table 3 Association between a high baPWV (≥1,750 cm/sec) and the covariates in the T2DM subjects
High baPWV
Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
GGT1 G allele 1.80 (1.16 - 2.78) 0.008 1.54 (0.97 - 2.43) 0.07
Age 1.11 (1.08 - 1.14) < 0.001 1.10 (1.07 - 1.13) < 0.001
Hypertension 3.84 (2.47 - 5.98) < 0.001 3.37 (2.11 - 5.38) < 0.001
Diabetes duration 1.06 (1.03 - 1.08) < 0.001 1.02 (0.997 - 1.05) 0.09
HDL-C < 1.0 mmol/L 1.71 (1.07 - 2.74) 0.03 1.40 (0.87 - 2.26) 0.16
Drinking 0.63 (0.42 - 0.94) 0.02 1.06 (0.66 - 1.69) 0.83
ALT 0.99 (0.98 - 1.00) 0.07 1.01 (0.99 - 1.02) 0.40
ALDH2*2 allele 1.43 (0.94 - 2.20) 0.099 1.47 (0.90 - 2.40) 0.13
GGT 1.00 (0.995 - 1.01) 0.60
Female 1.18 (0.75 - 1.85) 0.49
BMI 0.99 (0.93 - 1.05) 0.76
HbA1c 0.94 (0.84 - 1.05) 0.26
AST 1.01 (0.99 - 1.03) 0.52
LDL-C ≥ 3.6 mmol/L 0.84 (0.57 - 1.23) 0.37
Triglycerides ≥ 1.7 mmol/L 1.14 (0.77 - 1.69) 0.51
Bold typeface indicates data that are statistically significant. baPWV, brachial-ankle pulse wave velocity; T2DM, type 2 diabetes mellitus; OR, odds ratio; CI,
confidence interval; GGT, γ-glutamyltransferase; HDL-C, high-density lipoprotein cholesterol; ALT, alanine aminotransferase; ALDH2, aldehyde dehydrogenase 2;
BMI, body mass index; HbA1c, hemoglobin A1c; AST, aspartate aminotransferase; LDL-C, low-density lipoprotein cholesterol.
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Table 4 Interactive effects between the GGT1 genotype and serum HDL-C levels on the baPWV in the T2DM subjects
HDL-C GGT1 genotype High baPWV* baPWV (cm/sec)
OR† (95% CI) P-value B† SE P-value
≥ 1.0 mmol/L A/A genotype 1 - 0 - -
A/G or G/G genotype 1.49 (0.91 - 2.44) 0.11 47.38 38.60 0.22
<1.0 mmol/L A/A genotype 1.31 (0.73 - 2.35) 0.37 58.32 54.50 0.29
A/G or G/G genotype 2.49 (1.07 - 5.82) 0.04 150.84 79.19 0.06
Bold typeface indicates data that are statistically significant.
*baPWV ≥ 1750 cm/sec.
†Adjusted by age, hypertension, diabetes duration, drinking, ALT level and ALDH2*2 allele.
GGT, γ-glutamyltransferase; HDL-C, high-density lipoprotein cholesterol; baPWV, brachial-ankle pulse wave velocity; T2DM, type 2 diabetes mellitus; OR, odds ratio;
CI, confidence interval; B, partial regression coefficient; SE, standard error.
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were also higher in GGT1 G allele carriers with a low
HDL-C level than in non-carriers with a normal HDL-C
level (B: 150.84 cm/sec, P = 0.06). Moreover, the HDL-C
level at baseline was found to be a significant predictor of
a high baPWV at the last point of follow-up only in G allele
carriers according to the ROC curve analysis (AUC 0.63,
95%CI 0.52 - 0.74, P = 0.02) (Figure 1a and b). The optimal
cut-off value for the HDL-C level for predicting a high
baPWV in G allele carriers was 1.1 mmol/L (sensitivity:
46.3%; specificity: 74.5%).
In the general subjects, a significant interactive effect of
the GGT1 genotype and dyslipidemia on the baPWV
values was observed (P = 0.02). The mean baPWV values
in G allele carriers were significantly higher among the
subjects with dyslipidemia than those without dyslipidemia
(1,790.8 ± 370.4 cm/sec vs. 1,617.8 ± 347.8 cm/sec, P =
0.01), while the values did not differ in non-carriers. Simi-
larly, the mean baPWV values in G allele carriers were
higher among the subjects with a low HDL-C level than
those with a normal HDL-C level, although the difference
did not reach statistical significance (1,988.3 ± 381.4 cm/secTable 5 Association between the risk of DR and the covariate
in the multiple regression model
GGT1 A/A genotype
HR (95% CI) P
HbA1c 1.46 (1.23 - 1.73) <
Female 3.49 (1.25 - 9.72) 0
Age 0.94 (0.90 - 0.98) 0
ALDH2*2 allele 2.21 (0.99 - 4.91) 0
HDL-C 1.01 (0.99 - 1.04) 0
Diabetes duration 1.04 (0.97 - 1.11) 0
GGT 1.00 (0.98 - 1.01) 0
Hypertension 1.90 (0.74 - 4.90) 0
Drinking 1.45 (0.54 - 3.89) 0
ALT 1.00 (0.97 - 1.03) 0
Bold typeface indicates data that are statistically significant. DR, diabetic retinopath
CI, confidence interval; HbA1c, hemoglobin A1c; ALDH2, aldehyde dehydrogenase 2vs. 1,705.1 ± 367.8 cm/sec, P = 0.19) (Additional file 1: Table
S3). The HDL-C level was also significantly associated with
a high baPWV only in G allele carriers among the general
subjects (AUC 0.63, 95%CI 0.52 - 0.74, P = 0.02) (Additional
file 2: Figure S1a and b).
Forty-five (21.0%) patients were newly diagnosed with
DR during the observation period. The HbA1c level was
found to be the only risk factor for the incidence of DR
in the univariate regression model. When stratified by
the GGT1 genotype, the HbA1c level, a female gender
and age were identified to be significantly associated
with the incidence of DR in non-carriers, whereas the
diabetes duration, ALDH2*2 allele and HDL-C level
were significantly associated with the incidence of DR in
G allele carriers (Table 5). A significant interactive effect
of the GGT1 genotype and HDL-C level on the risk of
DR was also observed (P = 0.02).
Discussion
The novel findings of this study are as follows. First, a
GGT1 variant, rs4820599, the G allele and a low HDL-C
level were identified to be risk factors for a high baPWVs stratified by the GGT1 genotype in the T2DM subjects
GGT1 A/G or G/G genotype
-value HR (95% CI) P-value
0.001 1.17 (0.87 - 1.58) 0.30
.02 3.13 (0.74 - 13.33) 0.12
.005 1.02 (0.96 - 1.09) 0.49
.052 7.88 (1.53 - 40.54) 0.014
.35 0.94 (0.90 - 0.99) 0.02
.26 1.11 (1.01 - 1.23) 0.03
.50 1.02 (0.999 - 1.03) 0.07
.18 1.86 (0.46 - 7.61) 0.39
.46 1.89 (0.41 - 8.73) 0.42
.89 0.99 (0.97 - 1.02) 0.56
y; GGT, γ-glutamyltransferase; T2DM, type 2 diabetes mellitus; HR, hazard ratio;
; HDL-C, high-density lipoprotein cholesterol; ALT, alanine aminotransferase.
a G allele carriers
AUC: 0.63
P = 0.02 
b Non-carriers
AUC: 0.50
P = 0.97 
Figure 1 The ROC curves of HDL-C for high baPWV (≥1750 cm/sec)
in the GGT1 G allele carriers (a) and non-carriers (b) in T2DM subjects.
The HDL-C level at baseline was found to be a significant predictor of a
high baPWV at the last point of follow-up only in G allele carriers. The
optimal cut-off value for the HDL-C level for a high baPWV in G allele
carriers was 1.1 mmol/L (sensitivity: 46.3%; specificity: 74.5%).
AUC, area under the curve; CI, confidence interval; ROC, receiver
operating characteristic; HDL-C, high-density lipoprotein cholesterol;
baPWV, brachial-ankle pulse wave velocity; T2DM, type 2
diabetes mellitus.
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lysis. Interestingly, a significant interactive effect of the
GGT1 genotype and low HDL-C level on the risks ofboth a high baPWV and DR was found. Second, the
HDL-C level at baseline was identified to be a significant
predictor of a high baPWV only in G allele carriers
according to the ROC analysis. This result in the T2DM
patients was also noted in the general population. Third,
the GGT1 genotype was not associated with the risk of
DR, although it affected the principal factors involved in
the risk of DR. Fourth, the associations between the
levels of GGT and fasting plasma glucose, HDL-C and
LDL-C and between dyslipidemia and a high baPWV
were significant only in G allele carriers among the gen-
eral subjects. In this study, the triglyceride levels were
positively associated with the serum GGT levels but not
the risk of a high baPWV or DR, and the LDL-C levels
were positively associated with the serum GGT levels
only in the general subjects with the G allele.
The mean serum log GGT level was significantly
higher in G allele carriers than in non-carriers among
both the T2DM patients and the general population.
The expression of GGT increases as an adaptive re-
sponse to oxidative stress, although the mechanism
underlying GGT regulation in response to oxidative
stress remains unclear [9,32]. Human GGT is a multi-
gene family consisting of at least seven GGT genes or
pseudogenes, in which a major GGT1 and minor GGT5
have been found to encode proteins exhibiting GGT
activity [32]. A variant, rs4820599, on the GGT1 gene is
predicted to be located at a transcription factor binding
site, which can result in differential gene transcription,
according to FuncPred (http://snpinfo.niehs.nih.gov/
snpinfo/snpfunc.htm, accessed 3/31/2015). This fact may
explain the findings of the present study and previous
observations obtained using GWAS [27-29]. In addition
to GGT1, however, population-based GWAS have re-
vealed evidence of an association between the serum
GGT level and a series of SNPs in candidate genes, i.e.
HNF1A in various ethnic groups [27-29], C14orf73 and
RORA in subjects of European descent [29], MYL2,
C12olf51 and OAS1 in individuals of East Asian descent
[28] and ALDH2 in Japanese [33]. A pathway analysis of
the SNP associations showed significant overlap between
genes affecting the GGT level and those affecting common
metabolic and inflammatory diseases under the control of
the Hepatic Nuclear family [29]. Therefore, our results
provide only the first glimpse into the association between
one of these SNPs and the GGT level, factors affecting the
GGT level and the risk of vascular disease resulting from
metabolic and inflammatory diseases, as represented by
T2DM.
The baPWV is used in epidemiological and clinical re-
search as an index of arterial stiffness and atherosclerosis
and is indicated to be an independent predictor of CVD
[30,34-36]. A few epidemiological studies have examined
the association between the GGT level and baPWV,
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present study, the GGT1 G allele was identified to be a
risk factor for a high baPWV, while the GGT level was
found to be a risk factor in non-carriers. GGT is
expressed on the cell surface membrane of most cell
types, although only liver GGT is detected in the serum,
and the relationship between the cellular GGT and
serum GGT expressions is unknown [6,37]. The serum
GGT level appears to be associated with the risk of CVD
from the early stage of arterial stiffness through the
onset of CVD events [2,4,6,7,35,36,38]. This is because
oxidative stress, vascular inflammation and endothelial
dysfunction play a central role in the pathogenesis of
atherosclerosis [39,40], and because the serum GGT
level is proposed to be an early and sensitive marker of
oxidative stress [7,9,32]. A key question is whether the
serum GGT level is an simply innocent marker or
whether its activity is causally involved in the develop-
ment of arterial stiffness and atherogenesis, as shown in
atheroma plaques [6,7]. Cellular GGT is known to be
involved in the generation of reactive oxygen species in
the presence of transition metals and serum GGT is
speculated to promote the oxidation of circulating lipo-
proteins [6,7,9,41].
The serum HDL-C level has been reported to be in-
versely related to the baPWV in a general Chinese popu-
lation (50 to 90 years of age) and the aortic PWV in
other populations [42]. An isolated low HDL-C level is a
dyslipidemic phenotype that appears to be more preva-
lent among Asian populations, in whom low HDL-C
levels are strongly associated with an increased CHD
risk [43]. Several potential mechanisms may explain the
association between the serum HDL-C level and CVD
[15,20-22,42-44]. HDL has a role in reverse cholesterol
transport and other direct actions on numerous cell
types, thereby reducing cardiovascular risks. In endothe-
lial cells and their progenitors, HDL prevents apoptosis
and stimulates proliferation and migration. HDL also
has diverse anti-inflammatory actions in both endothelial
cells and leukocytes. In vascular smooth muscles, HDL
attenuates proinflammatory, promigratory and degradative
processes. HDL has an antithrombotic effect via its actions
on the endothelium and platelets. In addition, HDL
protects pancreatic β-cells from apoptosis, decreases the
white adipose tissue mass, increases energy expenditures
and promotes the production of adiponectin, which pos-
sesses its own vascular protective properties. However, the
classic HDL (concentration) hypothesis is gradually being
replaced by the triglyceride hypothesis and the HDL
function hypothesis due to the failure of clinical trials and
negative results for human genetics [12-14,18-22]. The
classic entity of ‘diabetic dyslipidemia’ is characterized by
the so-called atherogenic lipid triad, consisting of an in-
crease in small dense LDL particles and triglyceride-richlipoproteins and a decrease in HDL-C [12-17,22]. In this
study, the triglyceride levels were positively associated
with the serum GGT levels, but not any of the risk factors
for a high baPWV or DR in both the T2DM patients and
general subjects. In order to prove that a low HDL-C level,
rather than a high triglyceride level, is a risk factor for a
high PWV, we applied a multivariate model including
triglycerides on purpose despite the insignificance of this
parameter as a covariate. Most serum GGT is bound to
lipoproteins, more dominantly to Apo A than to Apo B,
although the ratio may change depending on the serum
lipid profile [6,8-11,41]. All things considered, the serum
GGT level is associated with cardiovascular risks, includ-
ing dyslipidemia, more greatly in G allele carriers than in
non-carriers, and coexisting low HDL-C may lead to in-
creased LDL-associated GGT and GGT-dependent LDL
oxidation followed by the possible development of signifi-
cant arterial stiffness in this population.
The interactive effect of the GGT1 genotype and a low
HDL-C level on the risk of DR was also significant in
the current study, and a low HDL-C level was found to
be an independent risk factor for DR only in G allele car-
riers. Oxidative stress plays a pivotal role in the develop-
ment of DR as well as macrovascular diseases [45-49]. The
metabolic abnormalities associated with diabetes cause
mitochondrial superoxide overproduction in the endothe-
lial cells of both small and large vessels [45,48,49]. This
increased superoxide production causes the activation of
major pathways involved in the pathogenesis of various
complications, such as polyol pathway flux as well as the
increased formation of advanced glycation end products,
activation of protein kinase C and over-activity of the hex-
osamine pathway [45,48,49]. The overexpression of super-
oxide dismutase in transgenic diabetic mice prevents DR,
nephropathy and cardiomyopathy [48,49]. In addition to
two principal and reversible risk factors for DR, blood glu-
cose and BP, a low HDL-C level is indicated to be a risk
factor for DR [16,23,25,46,49]. Many of the pathogenic ef-
fects of lipoproteins occur after these particles leak from
the circulation [16,25,49]. Du et al. [25] identified extrava-
sated Apo A1 and Apo B in human diabetic eyes and
showed that native HDL completely blocks oxidative
stress and the apoptosis of retinal pigment epithelial cells
induced by heavily oxidized glycated LDL, thereby sug-
gesting an important new role for extravasated and modi-
fied plasma lipoproteins in promoting DR. We speculate
that GGT may co-localize with extravasated HDL and
LDL and possibly take part in the pathogenesis of DR in G
allele carriers with a low HDL-C level. In the present
study, among G allele carriers, the diabetes duration and
ALDH2*2 allele were other independent risk factors for DR.
We previously reported a significant association between
the ALDH2*2 allele and DR, as follows: the incidence of DR
is significantly higher in ALDH2*2 allele carriers with a high
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than in non-carriers with a high or low GGT level; a high
GGT level in non-carriers is most significantly associated
with drinking habits, while that in ALDH2*2 allele carriers
is significantly associated with multiple cardiovascular risk
factors; and ALDH2 therefore may protect the vasculature
against reactive aldehydes generated under conditions of
sustained oxidative stress [50]. In non-carriers, a female
gender, age and the HbA1c level, which is associated with a
high GGT level, were found to be independent risk factors
for DR.
Diabetes and hypertension promote adverse changes
throughout the vascular tree, eliciting both macrovascu-
lar and microvascular complications [34,38,45,46]. In-
creased arterial stiffness and microvascular remodeling
are the most prevalent and earliest forms of organ dam-
age in these diseases [34,38,45,46]. Therefore, diabetic
subjects with a high PWV and/or MVCs appear to be
particularly prone to developing accelerated atheroscler-
osis and premature death [38,46,47]. A significant posi-
tive association between the presence of DR and baPWV
has been reported in Japanese T2DM patients without
macrovascular complications [34]. The association be-
tween a high baPWV and DR is likely to exist in G allele
carriers, although this finding did not reach statistical
significance in the present study due to the small sample
size (data not shown). Although fibrates fail to reduce
cardiovascular events in patients treated with statins in
general [14,18], fenofibrate has received major attention
as a novel medical treatment for DR and other diabetes-
induced MCVs [24]. This is because well-designed clin-
ical trials, i.e. the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) and ACCORD trials,
demonstrated large reductions in the progression of DR
and the subsequent need for laser intervention, in
addition to reductions in adverse renal and neurological
outcomes, in patients with T2DM [24]. Fenofibrate regu-
lates the expression of many different genes, with a range
of beneficial effects for lipid control, inflammation, angio-
genesis and cell apoptosis [24,51]. Interestingly, treatment
with 200 mg/day of fenofibrate for 48 weeks in patients
with non-alcoholic fatty liver disease was recently shown
to improve metabolic syndrome, in addition to glucose
and liver parameters, including a reduction in the serum
GGT level of 39% [51]. These findings and the current re-
sults suggest that the early detection and treatment of low
HDL-C levels in populations at high risk for MVC and
CVD, such as T2DM patients with arterial stiffness and/or
DR, may be an attractive therapeutic target for prevention
[6,7,15-17,24,34,38,45,46,51]. The GGT1 G allele is a novel
candidate risk factor in this population and we hope to
reanalyze the findings of previous clinical trials of agents
used to increase the HDL-C levels, stratifying the outcome
according to the GGT1 genotype.The strength of this study is that significant interactive
effects between the GGT1 genotype and a low HDL-C
level were observed on both a high baPWV and DR in
two different populations and different analyses. The
crucial limitations of this study include the retrospective
study design, small sample size and lack of information
on factors such as the effects of drug therapy, the HDL-
C fraction and function and specific biomarkers of oxi-
dative stress.
We herein presented for the first time the significant
interactive effects of the GGT1 G allele and a low HDL-
C level on a high baPWV and DR. These findings may
suggest a common pathological mechanism in case of
diabetic macro- and micro-angiopathy and prompt
repeat-analyses of previous trials according to the GGT1
genotype as well as the development of future clinical
trials comparing the efficacy of agents increasing the
HDL-C level in improving angiopathy between GGT1
genotypes. However, well-designed studies in larger
cohorts are still needed to further confirm our results.Additional files
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